Edmonston-Enders strain

Edmonston-Enders strain. It is a historic, attenuated strain of the measles virus, pivotal in the development of the first licensed measles vaccines. Isolated in the laboratory of Nobel laureate John F. Enders in Boston, this strain provided the foundational viral material for subsequent attenuation passages. Its successful adaptation to grow in non-human cell cultures represented a monumental breakthrough in virology and preventive medicine.

History and development

The strain originated from a blood sample taken from a young boy, David Edmonston, during a 1954 measles outbreak in Boston. The pioneering virologist John F. Enders, alongside his colleague Thomas C. Peebles, successfully isolated the virus in primary human kidney cell cultures at the Children's Hospital Boston. This critical work was conducted within the context of Enders' earlier, Nobel Prize-winning success with the poliovirus. Following initial isolation, the team, including further researchers like Samuel L. Katz and Milan V. Milovanović, undertook a series of sequential passages in various cell types. These passages included cultivation in embryonated chicken eggs and, most significantly, adaptation to grow in chicken embryo fibroblast cultures, a process that progressively attenuated its virulence.

Virology and characteristics

As a member of the genus Morbillivirus within the family Paramyxoviridae, the wild-type virus is highly contagious and pathogenic. The attenuation process for the Edmonston-Enders strain involved serial propagation in heterologous cell systems, which selected for viral variants with reduced ability to cause disease in humans. Key genetic adaptations occurred as it was passaged through cultures of chicken embryo fibroblasts, altering its replication dynamics. These changes rendered it immunogenic yet sufficiently weakened, a property crucial for its role as a vaccine seed virus. The strain's antigenic properties remained effectively intact, allowing it to induce a protective immune response comparable to natural infection.

Use in vaccine development

The attenuated Edmonston-Enders strain served as the direct progenitor for the first licensed measles vaccine in the United States, approved in 1963. Initial formulations, known as the Edmonston B vaccine, often required concurrent administration of measles immune globulin to mitigate febrile reactions. This spurred further research to develop even more attenuated derivatives. Work by Anton Schwarz at the Pitman-Moore company and by Maurice Hilleman at Merck & Co. led to the creation of the further-attenuated Schwarz and Moraten strains. Concurrently, scientists at the Institute of Immunology in Zagreb developed the high-titer Edmonston-Zagreb strain, which was later utilized in mass vaccination campaigns by the World Health Organization.

Impact and legacy

The development of vaccines from this strain fundamentally altered the global epidemiology of measles, a leading cause of childhood mortality prior to vaccination. In the United States, widespread use of its derivative vaccines led to a declaration of measles elimination in 2000 by the Centers for Disease Control and Prevention. The strain's legacy is integral to the World Health Organization's Expanded Programme on Immunization and its subsequent Measles & Rubella Initiative. The scientific principles of viral attenuation demonstrated with this strain informed later vaccine development for other diseases, including mumps, rubella, and rotavirus. Its history is a cornerstone narrative in the field of vaccinology.

Related strains and derivatives

Several critical vaccine strains were derived directly from sequential passages of the original isolate. The Moraten strain (meaning "More Attenuated Enders"), used in the M-M-R II vaccine by Merck & Co., is a primary example. The Schwarz strain, developed independently, saw extensive use globally and in combined vaccines like Priorix by GlaxoSmithKline. The Edmonston-Zagreb strain, notable for its high immunogenicity in young infants, was deployed in vaccination campaigns across parts of Africa and South America. Other research variants, developed at institutions like the Walter Reed Army Institute of Research, contributed to the broader understanding of measles virus immunology and pathogenesis.

Category:Virus strains Category:Vaccines Category:History of virology